Inhalation Anesthetics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Inhalation Anesthetics Market is Segmented by Type (Desflurane, Sevoflurane, Isoflurane, and Other Types), End-User (Hospital, Ambulatory Surgical Centers, Other End Users), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

inhalation anesthesia market overview
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.46 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The inhalation anesthetics market is estimated to be USD 1,223.08 million in 2021. It is expected to reach USD 1,580.98 million by 2027, registering a CAGR of 4.46% from 2022 to 2027.

The application of inhalation anesthetics for the diagnosis and treatment of COVID-19 and associated diseases has positively impacted the market's growth. Volatile agents are effective in patients who need complex and high sedation, significantly reducing or removing intravenous sedatives. Volatile agents contain mild muscle relaxation properties and may lower the usage of paralytic agents and benefit the lungs.

For instance, the article entitled “Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS” published in June 2020, states that isoflurane offers the highest potency with low dosing requirements for ICU patients. And these Volatiles are delivered to the patients through either an anesthesia machine or ICU ventilator with an in-line miniature vaporizer. These mini vaporizers are used to block the inhalation of carbon dioxide. And the article concluded that delivery of inhaled volatile sedation regimens with a good sedation profile might have benefits in the lung while easing pressure on essential sedative medications.

The market is expected to grow due to the increase in the number of surgeries performed globally. For instance, The Centre of Disease Control and Prevention (CDC) data updated in March 2022 related to Emergency Department Visits in the United States shows that, in the year 2018, 130 million emergency hospital visits and the number of injury-related visits were 35 million. This number increased from the prior year. In 2020, employers reported 2.7 million injury and illness cases in private industry. Injury cases declined to 2.1 million in 2020 from 2.7 million in 2019, while illness cases more than quadrupled to 544,600 cases in 2020, shows the United States Bureau Of Labor Statistics data. This surge in emergency cases and related increase in surgical interventions are among the few factors estimated to drive the growth of the studied market.

The factors, such as the increasing adoption rate of minimally invasive surgeries, are also helping the market growth due to their effectiveness in a lesser hospitalization period. Minimally invasive surgeries have been reported to cause less post-operative pain. Hence, the patients receive smaller dosages of painkillers. Additionally, as minimal cuts or stitches are involved, the hospital stay is relatively shorter, and the patients need not visit the hospital frequently. “Robotic Cardiac Surgery in Europe: Status 2020”, a study published in January 2022, concluded that 2,563 procedures were carried out during 4 years (2016–2019), including robotically assisted coronary bypass grafting, the perioperative rates of revision for bleeding, stroke, and mortality were 2.2%, 0.2%, and 1.1%, respectively.

However, side effects associated with the inhalation anesthetics, the lower adoption rate in case of inhaled anesthetics in certain surgical procedures, generic competition for almost all of the halogenated agents, and recent patent expiries are restraining the inhalation anesthetics market.

Scope of the Report

As per the scope of the report, inhalational anesthetics are used for the induction and maintenance of general anesthesia and sedation. The exact mechanisms by which they function are still unknown. The most common inhalational anesthetics are sevoflurane, desflurane, and nitrous oxide. Of these, sevoflurane is the most common due to its rapid onset of action and quick patient recovery. The Market is Segmented by Type (Desflurane, Sevoflurane, Isoflurane, and Other Types), End-User (Hospital, Ambulatory Surgical Centers, and Other End Users), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Type
Desflurane
Sevoflurane
Isoflurane
Other Types
End User
Hospitals
Ambulatory Surgical Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Sevoflurane Holds the Major Share in the Inhalation Anesthetics Market And Expected to do Same in the Forecast Period

Sevoflurane is the most widely used inhalation anesthetic, owing to its therapeutic advantages and low cost. Sevoflurane is an ether inhalation anesthetic agent with low pungency, a nonirritant odor, and a low blood-gas partition coefficient.

Sevoflurane is useful in adults and children for both induction and maintenance of anesthesia in inpatient and outpatient surgery. It is ideal for asthma patients or people with sensitized air passages. The drug can be administered without the use of an intravenous route. Sevoflurane is also used as an anesthetic gas for children, as it can be breathed in by a face mask and works very quickly in getting children off to sleep.

Factors include proven safety records of sevoflurane, increasing use for both outpatient and inpatient, increasing use for both human and veterinary healthcare, growing trends of cosmetic surgery and plastic surgery, and increasing incidences of orthopedic, onco-surgeries, and spinal surgeries, which are propelling the growth of sevoflurane. The segment is also benefitting from an increase in accidents and emergency cases. These drugs are given to patients before surgery to make induction of general anesthesia substantially easier.

Moreover, it has been observed that there is a significant focus on researching the combination of sevoflurane with other anesthesia drugs to enhance the efficacy of anesthesia in patients during surgical procedures.

As per the press release by International Institute for Integrative Sleep Medicine in February 2022, the researchers at the University of Tsukuba investigated the effect of the general anesthetic sevoflurane and said that sevoflurane could improve sleep alteration in response to inflammation. In January 2022, Dechra Pharmaceuticals announced the acquisition of Isoflurane USP Inhalant Anesthetic and Sevoflurane USP Inhalant Anesthetic from Halocarbon Life Sciences. These two inhalation anesthesia solutions are used in both human and animal medicine. Thus, due to the aforementioned factors, the overall market for sevoflurane will grow steadily over the forecast period of the study.

inhalation anesthesia market trends

North America Holds Major Share and Expected to do Same in the Forecast Period

Increased government funds for R&D of innovative inhalation anesthetic and a rise in cancer incidences are driving the overall growth of the North American inhalation anesthesia market. Furthermore, the market growth is fueled by an increase in the prevalence of diseases and surgical procedures performed for disease treatment and development. According to statistics published by the Government of Canada, released in November 2021, an estimated 229,200 Canadians will be diagnosed with cancer, and 84,600 will die from cancer every year. Lung, breast, colorectal, and prostate cancers are expected to remain the most diagnosed cancers, accounting for 46% of all diagnoses in 2021. According to their survey, breast cancer affects one out of every eight women at some point in their life. As the number of incidences of cancer increases, so does the urge to treat cancer with surgeries such as minimally invasive and open surgery, thus, driving demand for inhalation anesthetics over the forecast period.

In June 2020, Piramal Urgent Care (PCC) established a strategic partnership with Medivant Healthcare, a US-based pharmaceutical outsourcing facility, to help hospitals throughout the country solve the critical shortage of injectable drugs. In January 2019, Sandoz, a Novartis division, launched Desflurance Liquid for inhalation. It is the first generic version of Suprane to be released in the United States. In patients undergoing inpatient and outpatient surgery, this liquid is utilized as an inhalation agent to maintain and induce anesthesia. Therefore, rising incidences of chronic diseases and growing company activities will significantly drive the market in the regional market during the study period.

inhalation anesthesia market analysis

Competitive Landscape

Market players in the inhalation anesthetics market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. The key market players that hold significant shares in the inhalation anesthetics market include Abbvie Inc., Baxter, Piramal Enterprises Ltd, and Hikma Pharmaceuticals PLC, among others.

Recent Developments

· In February 2022, Sedana Medical AB announced the launch of Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) received European DCP approval in July 2021. Also, the product has received national approvals in 14 countries. Additional applications for marketing approval have been submitted in the same year, and in 2022, the company is expected to receive national approvals in Italy, Poland, Switzerland, and the United Kingdom.

· In April 2020, Blue-Zone Technologies Ltd. received a Drug Identification Number (DIN) from Health Canada for DESFLURANE, USP, an important drug used for general anesthesia. The DIN allows Blue-Zone to manufacture and market its branded generic medicine.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Geriatric Population Prone to Chronic Diseases

      2. 4.2.2 Increasing Number of Emergency Cases and Surgical Interventions

      3. 4.2.3 Growing Demand for Lesser Duration in Hospitalization

      4. 4.2.4 Increasing Accessibility to Health Services and Surgeries

    3. 4.3 Market Restraints

      1. 4.3.1 Generic Competition for Almost All Halogenated Agents

      2. 4.3.2 Side-effects of Inhaler Anesthesia Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type

      1. 5.1.1 Desflurane

      2. 5.1.2 Sevoflurane

      3. 5.1.3 Isoflurane

      4. 5.1.4 Other Types

    2. 5.2 End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Ambulatory Surgical Centers

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Merck KGaA

      3. 6.1.3 Baxter International Inc.

      4. 6.1.4 Fresenius Kabi AG (Fresenius SE& Co. KGaA)

      5. 6.1.5 Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)

      6. 6.1.6 Hikma Pharmaceuticals PLC

      7. 6.1.7 Jiangsu Hengrui Medicine Co. Ltd

      8. 6.1.8 Lunan Pharmaceutical Group Co. Ltd

      9. 6.1.9 Piramal Enterprises Limited

      10. 6.1.10 Troikaa Pharmaceuticals Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Inhalation Anesthetics Market market is studied from 2019 - 2027.

The Inhalation Anesthetics Market is growing at a CAGR of 4.46% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Baxter, Lunan Pharmaceutical Group Co. Ltd, Piramal Enterprises Limited, Fresenius Kabi, Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC) are the major companies operating in Inhalation Anesthetics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!